215
Views
8
CrossRef citations to date
0
Altmetric
POLYCYSTIC OVARY SYNDROME

Galectin-3 is a potential biomarker to insulin resistance and obesity in women with polycystic ovary syndrome

, , , , , , & ORCID Icon show all
Pages 760-763 | Received 12 Jul 2019, Accepted 03 Mar 2020, Published online: 11 Mar 2020
 

Abstract

Polycystic ovary syndrome (PCOS) is the most common endocrine and metabolic disorder that affects women in reproductive age. This study aimed to evaluate Gal-3 levels and its role on metabolic parameters in women with PCOS. Gal-3 was measured in 44 PCOS and 25 women recruited as control group for the case-control study. Gal-3 levels were similar between PCOS and control groups (p > 0.05), but showed a positive correlation with glucose levels in the oral glucose tolerance test (OGTT) (r = 0.403, p = 0.037), body mass index (BMI) (r = 0.469, p = 0.027), insulin levels (r = 0.453, p = 0.030) and HOMA-IR (r = 0.738, p = 0.037) in PCOS group. The data suggest that Gal-3 plays a role in the pathophysiology of the insulin resistance and obesity in PCOS group.

摘要

多囊卵巢综合征(PCOS)是影响育龄期女性最常见的内分泌和代谢疾病。本研究旨在评估PCOS患者的Gal-3水平及其对代谢参数的影响。这是一个病例对照研究, 检测了44例PCOS患者以及25例对照组患者的Gal-3水平。两组人群的Gal-3水平相似(P>0.05), 但是在PCOS组, Gal-3水平与OGTT试验中的血糖水平(r=0.403, p=0.037), BMI(r=0.469, p=0.027), 胰岛素水平(r=0.453, p=0.030)以及HOMA-IR(r=0.738, p=0.037)呈正相关。结果提示我们, Gal-3水平在PCOS患者胰岛素抵抗和肥胖的病理生理中发挥作用。

The Chinese abstracts are translated by Prof. Dr. Xiangyan Ruan and her team: Beijing Obstetrics and Gynecology Hospital, Capital Medical University, Beijing 100026, China.

Disclosure statement

No potential conflict of interest was reported by the author(s).

Additional information

Funding

Fundação de Amparo à Pesquisa do Estado de Minas Gerais (FAPEMIG), Coordenação de Aperfeiçoamento de Pessoal de Nível Superior (CAPES), Conselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq/Brazil) by the financial support. FMR and KBG are grateful to CNPq Research Fellowship (PQ).

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.